BioCentury | Mar 23, 2009
Company News

Glide Pharma, Lipoxen deal

...The companies will evaluate Lipoxen's SuliXen long-acting insulin with Glide's Glide Solid Dose Injector (SDI) needle-free...
BioCentury | Mar 16, 2009
Clinical News

SuliXen: Final Phase I data

...0.1 and 0.3 IU/kg subcutaneous SuliXen was more potent than 0.2 IU/kg Lantus insulin glargine. SuliXen...
...profile, reaching maximum blood concentrations within 3 hours and remaining in circulation for 20-30 hours. SuliXen...
...events. sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) markets Lantus. Lipoxen plc (LSE:LPX), London, U.K. Product: SuliXen...
BioCentury | Jun 2, 2008
Clinical News

SuliXen: Interim Phase I data

...patients in an ongoing, Russian Phase I trial showed that 0.1 and 0.3 IU/kg of SuliXen...
...Group (Euronext:SAN; NYSE:SNY, Paris, France) markets Lantus insulin glargine. Lipoxen plc (LSE:LPX), London, U.K. Product: SuliXen...
BioCentury | Feb 4, 2008
Clinical News

SuliXen: Phase I started

...Russian Phase I trial in 12 healthy volunteers to compare 0.11 U/kg and 0.31 U/kg SuliXen...
...insulin glargine from sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France). Lipoxen plc (LSE:LPX), London, U.K. Product: SuliXen...
BioCentury | Oct 8, 2007
Clinical News

SuliXen: Start pilot trial

...year, LPX will start a pilot trial in patients. Lipoxen plc (LSE:LPX), London, U.K. Product: SuliXen...
Items per page:
1 - 5 of 5